AU2014224727B2 - Methods and compositions for the diagnosis of Alzheimer's disease - Google Patents

Methods and compositions for the diagnosis of Alzheimer's disease Download PDF

Info

Publication number
AU2014224727B2
AU2014224727B2 AU2014224727A AU2014224727A AU2014224727B2 AU 2014224727 B2 AU2014224727 B2 AU 2014224727B2 AU 2014224727 A AU2014224727 A AU 2014224727A AU 2014224727 A AU2014224727 A AU 2014224727A AU 2014224727 B2 AU2014224727 B2 AU 2014224727B2
Authority
AU
Australia
Prior art keywords
alpha
complement
apolipoprotein
antichymotrypsin
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014224727A
Other languages
English (en)
Other versions
AU2014224727A1 (en
Inventor
Peter Fitzgerald
John Lamont
Ivan McConnell
Ciaran RICHARDSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Randox Teoranta
Original Assignee
Randox Teoranta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Randox Teoranta filed Critical Randox Teoranta
Publication of AU2014224727A1 publication Critical patent/AU2014224727A1/en
Application granted granted Critical
Publication of AU2014224727B2 publication Critical patent/AU2014224727B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Epidemiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Biology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
AU2014224727A 2013-03-05 2014-03-04 Methods and compositions for the diagnosis of Alzheimer's disease Active AU2014224727B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1303936.7A GB2511525A (en) 2013-03-05 2013-03-05 Methods and Compositions for the Diagnosis of Alzheimer's Disease
GB1303936.7 2013-03-05
PCT/EP2014/054185 WO2014135546A1 (en) 2013-03-05 2014-03-04 Methods and compositions for the diagnosis of alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2014224727A1 AU2014224727A1 (en) 2015-08-13
AU2014224727B2 true AU2014224727B2 (en) 2020-09-03

Family

ID=48142456

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014224727A Active AU2014224727B2 (en) 2013-03-05 2014-03-04 Methods and compositions for the diagnosis of Alzheimer's disease

Country Status (9)

Country Link
US (1) US20160097780A1 (cg-RX-API-DMAC10.html)
EP (1) EP2965090B1 (cg-RX-API-DMAC10.html)
JP (1) JP6430413B2 (cg-RX-API-DMAC10.html)
CN (1) CN105164536B (cg-RX-API-DMAC10.html)
AU (1) AU2014224727B2 (cg-RX-API-DMAC10.html)
CA (1) CA2900002C (cg-RX-API-DMAC10.html)
ES (1) ES2674526T3 (cg-RX-API-DMAC10.html)
GB (1) GB2511525A (cg-RX-API-DMAC10.html)
WO (1) WO2014135546A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504432D0 (en) * 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
JP6702836B2 (ja) * 2016-09-28 2020-06-03 ハルメク・ベンチャーズ株式会社 認知症判定得点算出装置及びそのプログラム
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
CN118866316A (zh) * 2017-10-31 2024-10-29 通用电气健康护理有限公司 用于诊断认知疾病病理和/或结果的医疗系统
JP6950952B2 (ja) * 2017-12-20 2021-10-13 国立大学法人三重大学 脳アミロイド血管症の末梢血バイオマーカー
CN108681748A (zh) * 2018-05-18 2018-10-19 宝枫生物科技（北京）有限公司 判别轻度认知障碍的模型选择处理方法及装置
JP7437376B2 (ja) * 2018-07-19 2024-02-22 ジェネンテック，インコーポレーテッド マーカー分子に基づいて、アミロイド陽性認知症を罹患していると、または発症するリスクがあると個体を同定する方法、および関連する使用
CN110464833A (zh) * 2019-09-04 2019-11-19 北京豪思生物科技有限公司 铜蓝蛋白的应用
WO2021071219A1 (ko) * 2019-10-07 2021-04-15 조한나 퇴행성 신경질환의 진단용 바이오마커
JP7109499B2 (ja) * 2020-05-07 2022-07-29 一般社団法人脳と心の健康科学研究所 認知症判定得点算出装置及びそのプログラム
CN115066615A (zh) * 2020-12-28 2022-09-16 株式会社Mcbi 判定辅助信息生成方法、判定辅助信息生成系统以及信息处理装置
ES2924776A1 (es) * 2021-03-25 2022-10-10 Univ Castilla La Mancha Metodos para el diagnostico y pronostico de la enfermedad de alzheimer
CN112858697B (zh) * 2021-03-29 2024-03-01 鲁东大学 ALG-2-interacting protein X在制备分子标志物中的应用
CN114634970A (zh) * 2022-03-29 2022-06-17 南通惠皓医疗科技有限公司 遗传性阿尔兹海默症致病基因panel检测方法
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用
WO2024004944A1 (ja) * 2022-06-28 2024-01-04 株式会社Mcbi 判定支援情報生成方法、判定支援情報生成システム、及び情報処理装置
CN116063447B (zh) * 2022-09-13 2023-11-03 北京湃德智健科技有限公司 用于检测adap自身抗体的抗原多肽及其应用
US20240138749A1 (en) * 2022-10-31 2024-05-02 Movalytix, Inc. Method for screening of movement disorders
CN119495355B (zh) * 2024-10-31 2026-04-24 山东大学 一种阿尔兹海默症诊断标志物的筛选方法和系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106886A1 (en) * 2012-01-20 2013-07-25 Adelaide Research & Innovation Pty Ltd Biomarkers for gastric cancer and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH067191A (ja) * 1991-09-26 1994-01-18 Konica Corp モノクローナル抗体、それを産生するハイブリド−マ、その対応抗原及びそれを用いた測定方法
US5652352A (en) * 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene
AT411014B (de) * 2001-04-30 2003-09-25 Vitateq Biotechnology Gmbh Präparationen von vitamin e in kombination mit afamin
DE60225821T2 (de) * 2001-10-04 2009-04-30 Immuno-Biological Laboratories Co., Ltd., Takasaki Reagens zum Nachweis eines Risikofaktors der Alzheimer-Krankheit, Nachweiskit dafür und Verfahren zum Nachweis eines Risikofaktors der Alzheimer-Krankheit unter ihrer Verwendung
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006108051A2 (en) * 2005-04-05 2006-10-12 Neurodx, Llc Compositions and methods relating to alzheimer's disease
GB0512401D0 (en) * 2005-06-17 2005-07-27 Randox Lab Ltd Method
US7575876B2 (en) * 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
AT505727B1 (de) * 2007-09-04 2009-06-15 Univ Innsbruck Verfahren zur diagnose des metabolischen syndroms
GB0921447D0 (en) * 2009-12-04 2010-01-20 Randox Lab Ltd Assay
CA2799351A1 (en) * 2010-05-14 2011-11-17 Rules-Based Medicine, Inc. Methods and devices for diagnosing alzheimers disease
ITMI20120865A1 (it) * 2012-05-18 2013-11-19 Antonio Bertolotto Biomarcatori per patologie del sistema nervoso centrale

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106886A1 (en) * 2012-01-20 2013-07-25 Adelaide Research & Innovation Pty Ltd Biomarkers for gastric cancer and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JERKOVIC L ET AL, "Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression", JOURNAL OF PROTEOME RESEARCH, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, (2005-05-01), vol. 4, no. 3, pages 889 - 899 *

Also Published As

Publication number Publication date
EP2965090B1 (en) 2018-04-25
JP2016511406A (ja) 2016-04-14
CN105164536A (zh) 2015-12-16
ES2674526T3 (es) 2018-07-02
EP2965090A1 (en) 2016-01-13
GB201303936D0 (en) 2013-04-17
AU2014224727A1 (en) 2015-08-13
JP6430413B2 (ja) 2018-11-28
CA2900002C (en) 2022-01-25
US20160097780A1 (en) 2016-04-07
GB2511525A (en) 2014-09-10
CA2900002A1 (en) 2014-09-12
WO2014135546A1 (en) 2014-09-12
CN105164536B (zh) 2018-02-06

Similar Documents

Publication Publication Date Title
CA2900002C (en) Methods and compositions for the diagnosis of alzheimer's disease
US20120178637A1 (en) Biomarkers and methods for detecting alzheimer's disease
CN105849566B (zh) 肾脏疾病生物标志物
EP2504455A1 (en) Methods, kits and reagents for diagnosing, aiding diagnosis and/or monitoring progression of a neurological disorder
CA2913524C (en) Method for aiding differential diagnosis of stroke
CN112567246A (zh) 治疗脊髓性肌萎缩症的方法
US20220003787A1 (en) Biomarker proteins for diagnosing alzheimer's dementia and use thereof
CN104272112A (zh) 用于帮助诊断中风的基于生物标记的方法和生物芯片
US10078089B2 (en) Compositions and methods for treating steroid resistant nephrotic syndrome and/or steroid sensitive nephrotic syndrome
US12174187B2 (en) Methods for detecting multiple sclerosis (MS) diagnostic autoantibodies
CN104704365B (zh) 精神分裂症标记物组及其利用
KR20230028619A (ko) 아토피성 피부염 진단용 바이오마커 및 이의 용도
CN116445606A (zh) 血清分子标志物comp在辅助诊断抑郁症中的应用
KR102435331B1 (ko) Hook2를 포함하는 천식 진단용 바이오마커 조성물
KR102232200B1 (ko) 알츠하이머치매 진단 바이오마커
CN116773825B (zh) 诊断急性川崎病的血液生物标志物和方法
CN120818608B (zh) Meis3作为肥厚性心肌病生物标志物的应用
CN119859676A (zh) 鉴别感染性肺炎诱发的脓毒症和非感染性肺病的生物标志物及其用途
CN119120680A (zh) Zcchc2在干燥综合征诊断与区分系统性红斑狼疮中的用途
CN119859677A (zh) CCNA1、CHIT1、C9orf103在鉴别感染性肺炎诱发的脓毒症和非感染性肺病中的应用
CN119120679A (zh) Klhdc8b在系统性红斑狼疮诊断中的应用
CN118028453A (zh) Cxcl1和tnfrsf12a在aki诊断中的应用
WO2021024009A1 (en) Methods and compositions for providing colon cancer assessment using protein biomarkers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)